The controls were not matched to cases for body mass index, prior chemotherapy, time since diagnosis, or characteristics other than those stated above.Eligible patients were required to have been taking an AI or SERM as adjuvant therapy or for breast cancer risk reduction and to have had the additional diagnosis of atrophic vaginitis, as determined by symptoms such as vaginal dryness, dyspareunia,